Andrew Cooper
Stock Analyst at Raymond James
(3.29)
# 1,067
Out of 5,127 analysts
151
Total ratings
48.51%
Success rate
2.18%
Average return
Main Sectors:
Stocks Rated by Andrew Cooper
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| AZTA Azenta | Maintains: Outperform | $35 → $45 | $37.50 | +20.00% | 3 | Nov 25, 2025 | |
| ITGR Integer Holdings | Reiterates: Outperform | $143 → $95 | $82.79 | +14.75% | 4 | Oct 24, 2025 | |
| HOLX Hologic | Downgrades: Market Perform | n/a | $74.88 | - | 13 | Oct 22, 2025 | |
| AVTR Avantor | Maintains: Outperform | $14 → $16 | $12.06 | +32.67% | 16 | Oct 16, 2025 | |
| HAE Haemonetics | Downgrades: Outperform | $105 → $78 | $84.04 | -7.19% | 10 | Aug 11, 2025 | |
| GH Guardant Health | Maintains: Outperform | $59 → $61 | $108.74 | -43.90% | 4 | Jul 31, 2025 | |
| RVTY Revvity | Reiterates: Outperform | $120 → $115 | $101.71 | +13.07% | 9 | Jul 29, 2025 | |
| TMO Thermo Fisher Scientific | Reiterates: Outperform | $525 → $535 | $606.50 | -11.79% | 7 | Jul 24, 2025 | |
| MYGN Myriad Genetics | Reiterates: Outperform | $19 → $10 | $6.56 | +52.44% | 5 | May 7, 2025 | |
| FLGT Fulgent Genetics | Reiterates: Outperform | $24 → $25 | $27.89 | -10.36% | 2 | May 5, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Market Perform | n/a | $255.42 | - | 1 | Mar 28, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Market Perform | n/a | $235.00 | - | 8 | Feb 3, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Market Perform | n/a | $101.78 | - | 8 | Sep 26, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Market Perform | n/a | $17.22 | - | 16 | May 13, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Outperform | $68 → $85 | $239.56 | -64.52% | 5 | Feb 20, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Outperform | $100 → $76 | $33.51 | +126.80% | 12 | Feb 14, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Market Perform | n/a | $5.43 | - | 1 | Jul 19, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Market Perform | n/a | $12.83 | - | 14 | May 16, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Market Perform | n/a | $43.56 | - | 8 | Jan 18, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Market Perform | n/a | $2.66 | - | 5 | Sep 22, 2021 |
Azenta
Nov 25, 2025
Maintains: Outperform
Price Target: $35 → $45
Current: $37.50
Upside: +20.00%
Integer Holdings
Oct 24, 2025
Reiterates: Outperform
Price Target: $143 → $95
Current: $82.79
Upside: +14.75%
Hologic
Oct 22, 2025
Downgrades: Market Perform
Price Target: n/a
Current: $74.88
Upside: -
Avantor
Oct 16, 2025
Maintains: Outperform
Price Target: $14 → $16
Current: $12.06
Upside: +32.67%
Haemonetics
Aug 11, 2025
Downgrades: Outperform
Price Target: $105 → $78
Current: $84.04
Upside: -7.19%
Guardant Health
Jul 31, 2025
Maintains: Outperform
Price Target: $59 → $61
Current: $108.74
Upside: -43.90%
Revvity
Jul 29, 2025
Reiterates: Outperform
Price Target: $120 → $115
Current: $101.71
Upside: +13.07%
Thermo Fisher Scientific
Jul 24, 2025
Reiterates: Outperform
Price Target: $525 → $535
Current: $606.50
Upside: -11.79%
Myriad Genetics
May 7, 2025
Reiterates: Outperform
Price Target: $19 → $10
Current: $6.56
Upside: +52.44%
Fulgent Genetics
May 5, 2025
Reiterates: Outperform
Price Target: $24 → $25
Current: $27.89
Upside: -10.36%
Mar 28, 2025
Initiates: Market Perform
Price Target: n/a
Current: $255.42
Upside: -
Feb 3, 2025
Downgrades: Market Perform
Price Target: n/a
Current: $235.00
Upside: -
Sep 26, 2024
Reiterates: Market Perform
Price Target: n/a
Current: $101.78
Upside: -
May 13, 2024
Downgrades: Market Perform
Price Target: n/a
Current: $17.22
Upside: -
Feb 20, 2024
Downgrades: Outperform
Price Target: $68 → $85
Current: $239.56
Upside: -64.52%
Feb 14, 2024
Downgrades: Outperform
Price Target: $100 → $76
Current: $33.51
Upside: +126.80%
Jul 19, 2023
Initiates: Market Perform
Price Target: n/a
Current: $5.43
Upside: -
May 16, 2023
Downgrades: Market Perform
Price Target: n/a
Current: $12.83
Upside: -
Jan 18, 2023
Downgrades: Market Perform
Price Target: n/a
Current: $43.56
Upside: -
Sep 22, 2021
Downgrades: Market Perform
Price Target: n/a
Current: $2.66
Upside: -